Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: A pilot study

Journal of Chemotherapy

Volumn 15, Issue 4, 2003, Pages 387-393

  Tsitsilonis, Ourania E ^a   Tsavaris, N B ^a   Kosmas, C ^a   Gouveris, P ^a   Papalambros, E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adjuvant immunotherapy; Colorectal cancer; Cytokines; Monoclonal antibody 17 1A

Indexed keywords

CYTOKINE; DIMETINDENE; EDRECOLOMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CYTOLYSIS; CYTOTOXICITY; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL;

EID: 0042347817     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.4.387     Document Type: Article

References (29)

1. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993; 29A: 2077-2079.
2. Punt CJA. New drugs in the treatment of colorectal carcinoma. Cancer 1998; 83: 679-689.
3. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994; 125: 437-446.
4. Li W, Berencsi K, Basak S et al. Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J Immunol 1997; 159: 763-769.
5. Herlyn DM, Steplewski Z, Herlyn MF, Kopowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980; 40: 717-721.
6. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001; 40: 17-24.
7. Riethmuller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788-1794.
8. Punt CJA, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and follinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360: 671-677.
9. Flieger D, Spengler U, Beier I et al. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines. Hybridoma 1999; 18: 63-68.
10. Hjelm Skog A, Ragnhammar P, Fagerberg J et al. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol Immunother 1999; 48: 463-470.
11. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995; 92: 4773-4777.
12. Baxevanis CN, Voutsas JF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000; 164: 3902-3912.
13. Baxevanis CN, Tsavaris NB, Papadhimitriou SI et al. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumors receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer 1997; 33: 1202-1208.
14. Baxevanis CN, Papilas K, Dedoussis GVZ, Pavlis T, Papamichail M. Abnormal cytokine levels correlate with impaired cellular immune responses after surgery. Clin Immunol Immunopathol 1994; 71: 82-88.
15. Pawelec G, Rees RC, Kiessling R et al. Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncogenesis 1999; 10: 83-127.
16. Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995; 31: 1255-1263.
17. Adkins JC, Spencer CN. Edrecolomab (monoclonal antibody 17-1A). Drugs 1998; 56: 619-628.
18. Reali E, Guilani AL, Spisani S et al. Interferon-? enhances monoclonal antibody 17-1A-dependent neutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16. Clin Immunol Immunopathol 1994; 71: 105-112.
19. Nakayama Y, Shibao K, Sako T et al. Serum levels of interleukin-12 in patients with gastrointestinal cancer. Anticancer Res 2000; 20: 635-640.
20. Elsasser-Beile U, Kolble N, Grussenmeyer T, Wetterauer U, Schuttze-Seemann W. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin-2, interferon-alpha and retinoic acid. Anticancer Res 1998; 18: 1883-1890.
21. Chen YM, Ting CC, Pang JW et al. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs interleukin-2. J Interferon Cytokine Res 2000; 20: 31-39.
22. Bungard S, Flieger D, Schweitzer S, Sauerbruch T, Spengler U. The combination of interleukin-2 and interferon-α effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29. Cancer Immunol Immunother 1998; 46: 213-220.
23. Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt-Wolf I. Combinations of the cytokines IL-12, IL-2 and IFN-α significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2. Cytokine 2000; 12: 756-761.
24. Gosselin J, Tomolu A, Gallo RC, Flamand L. Interleukin-15 as an activator of natural killer cell-mediated antiviral response. Blood 1999; 94: 4210-4219.
25. Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt-Wolf IG. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A. Z Gastroenterol 2000; 38: 615-622.
26. Stetye J, Ragnhammar P, Liljefors M et al. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1998; 4: 1921-1929.
27. Deehan DJ, Heys SD, Simpson WC, Broom J, Franks C, Eremin O. In vivo cytokine production and recombinant interleukin-2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer 1994; 69: 1130-1135.
28. Y antigen expression. Clin Exp Immunol 2001; 123: 9-14.
29. Meyaard L, van der Vuurst de Vries AR, de Ruiter T, Lanier LL, Phillips JH, Clevers H. The epithelial cellular adhesion molecule (Ep-CAM) is a ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR). J Exp Med 2001; 194: 107-112.